Promises
4 promises
Promise Tracker
0 delivered, 0 close, 4 missed.
View Promises →
Ajanta Pharma Limited — Q1 FY25
Ajanta Pharma delivered a strong Q1 FY25 with revenue of INR 1,145 crore (+12% YoY) and EBITDA of INR 330 crore (+22% YoY), driven by branded generics growth of 17%.
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Ajanta Pharma delivered a strong Q1 FY25 with revenue of INR 1,145 crore (+12% YoY) and EBITDA of INR 330 crore (+22% YoY), driven by branded generics growth of 17%. Africa branded business rebounded sharply (+45% YoY) aided by a low base and spillover from Q4. India business grew 8.9%, outpacing IPM by 130 bps. EBITDA margin expanded to 29% (vs 27% in Q4 FY24) due to favorable mix and lower expenses. Management guided for low-teens revenue growth in FY25, with branded generics mid-teens, US mid-single-digit, and Africa institutional degrowth. EBITDA margin is expected to sustain around 29% ±1%. Key risk: Africa institutional business remains unpredictable due to reliance on procurement schedules.
अजंता फार्मा ने वित्त वर्ष 2025 की पहली तिमाही में अच्छा प्रदर्शन किया। कंपनी की कमाई ₹1,145 करोड़ रही, जो पिछले साल से 12% ज़्यादा है। मुनाफा (EBITDA) ₹330 करोड़ रहा, जो 22% बढ़ा। इसकी वजह ब्रांडेड जेनेरिक दवाओं की बिक्री में 17% का उछाल है। अफ्रीका में कारोबार में 45% की तेज़ी आई, क्योंकि पिछली तिमाही का असर और कम आधार था। भारत में बिक्री 8.9% बढ़ी, जो बाजार की तुलना में बेहतर है। मुनाफा मार्जिन 29% हो गया, जो पिछली तिमाही में 27% था। कंपनी को इस साल 10-13% कमाई बढ़ने की उम्मीद है। अफ्रीका में सरकारी ऑर्डर पर निर्भरता जोखिम है।
Promises0 met · 4 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Africa institutional business unpredictability
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Branded generics growth
17%
+17% YoY
Branded generics revenue grew 17% YoY to INR 860 crore, driven by strong performance in Africa and India.
Africa branded growth
45%
+45% YoY
Africa branded sales surged to INR 230 crore, benefiting from a low base due to prior year disruptions.
India PCPM
INR 4 lakh
+14% YoY
India per capita per month (PCPM) improved to INR 4 lakh from INR 3.5 lakh in Q1 FY24.
Capacity utilization
60-65%
N/A
Overall plant capacity utilization is around 60-65%, indicating room for volume growth without major capex.
What Changed vs Last Quarter
NEW
US ANDA filings of 8-12 in FY25
Target to file 8-12 ANDAs in the current fiscal year, with launches skewed towards Q3 and Q4.
UPDATED
FY25 revenue growth in low teens
Overall revenue expected to grow in low teens, with branded generics mid-teens, US mid-single digit, and Africa institutional degrowth.
UPDATED
EBITDA margin around 29% ±1% for FY25
EBITDA margin expected to remain in the range of 28-30% for the full year, supported by stable gross margins and controlled expenses.
UPDATED
CapEx of INR 175 crore for FY25
Capital expenditure for FY25 estimated at INR 175 crore, including maintenance capex.
DROPPED
India business to grow 10-11% in FY25
India branded generics are expected to grow 200-300 bps faster than IPM (forecast ~8%), implying 10-11% growth.
NEW RISK
Freight cost headwind of INR 30 crore
Management expects an adverse impact of INR 30 crore in freight costs for FY25 compared to FY24, assuming current rates persist.
NEW RISK
US price erosion in high single digits
US generic price erosion remains stable but at high single digits, which could pressure margins if competition intensifies.
NEW RISK
Employee cost one-time charge normalization
Q1 employee costs included a one-time INR 30 crore gratuity policy change; while normalized in subsequent quarters, it highlights potential for future policy-driven cost increases.
RISK GONE
Red Sea freight disruption impact
Increased transit times and freight costs due to Red Sea crisis could add ~INR 30 crore to expenses, potentially pressuring margins.
RISK GONE
US price erosion may be higher than guided
An analyst questioned whether high single-digit price erosion is aggressive; management acknowledged it's their estimate but could be worse.
RISK GONE
M&A valuations remain high for premium assets
Management noted that while valuations have tapered, premium specialty portfolios are still expensive, limiting inorganic growth options.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
Chantix launch is delayed to Q4 FY24 or Q1 FY25; any further delay could impact US revenue expectations.
Mentioned in Q3 FY24, Q4 FY24
India branded generics are expected to grow 200-300 bps faster than IPM (forecast ~8%), implying 10-11% growth.
Mentioned in Q3 FY24, Q4 FY24
Increased transit times and freight costs due to Red Sea crisis could add ~INR 30 crore to expenses, potentially pressuring margins.
Fast read
Guidance and risk preview
Overall revenue expected to grow in low teens, with branded generics mid-teens, US mid-single digit, and Africa institutional degrowth.
Africa institutional revenue fell 36% YoY due to procurement schedule shifts; management noted this business remains unpredictable.
View Risks →